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Objective. The technical and clinical outcome of endovascular revascularization was analyzed in patients with suspicion of
chronic splanchnic syndrome (CSS).
Methods.Medical history, duplex, angiography and exercise gastric tonometry suggested CSS in 97 patients. Twenty-seven
of them were treated endovascular (one patient had 3-vessel, 12 patients had 2-vessels, 14 patients had 1-vessel CSS). Five
patients received previous splanchnic revascularization. Twenty-three patients (85%) had severe co-morbidity: cardiac,
pulmonary or cachexia. Endovascular treatment consisted of percutaneous transluminal angiography (PTA) of the coeliac
artery (CA) or superior mesenteric artery (SMA) in three and primary balloon expandable stenting in 24 patients (13 CA
and 10 SMA solitary, two CA and SMA both, 31 splanchnic arteries in total).
Results. Three patients showed procedure related complications (11%). Mean follow-up was 19, range 2–76 months. Two
patients died during follow up, both not procedure or CSS related. Five patients had no improvement of symptoms, without
evidence of re- or residual stenosis. The primary clinical success was 67%, secondary clinical success was 81%. The primary
patency was 81% and secondary patency was 100%.
Conclusion. Endovascular treatment of CSS has a reasonable outcome. It is an alternative to operative treatment, especially
in patients with high co-morbidity or limited life expectancy.
Key Words: Chronic splanchnic syndrome; Mesenteric ischemia; Atherosclerosis; Endovascular treatment; Balloon
expandable stent.
Introduction
Chronic splanchnic syndrome (CSS) is defined as
symptomatic single or multiple splanchnic vessel
stenosis. It has to be differentiated from chronic
splanchnic disease (CSD), where obliterative splanch-
nic vascular disease is observed, but without symp-
toms. The prevalence of $50% stenosis of at least one
of the splanchnic artery origins, ranges from 10 to 24%
in unselected autopsy studies and selected angio-
graphy studies.1,2 It is assumed that abundant collat-
eral circulation is responsible for the absence of CSS in
most of the patients with CSD, hence many patients
will remain asymptomatic.
The classical triad of postprandial abdominal pain, a
bruit in the upper abdomen andweight loss, is observed
in less than half of the patients with CSS. The clinical
picture can be quite non-specific with presenting
symptoms like: gastritis, stomach ulceration, gastro-
paresis, mild diarrhea or abdominal symptoms related
to physical exercise. The diagnosis CSS should be
considered in every patient with unexplained chronic
abdominal complaints in combinationwith a significant
stenotic lesion in one or more splanchnic arteries. It is
widelyaccepted thatpatientswithsymptomatic stenosis
are potential candidates for treatment.
Treatment modalities available include surgical or
endovascular techniques. Vascular reconstructive sur-
gery offers excellent short and long-term results.3–5
Complication rates increase in patients in poor nutri-
tional state and with serious co-morbidity.6,7 Endovas-
cular treatment has been used in selected cases.8–14
Similar todevelopments in themanagementof renal and
iliac atherosclerotic disease, endovascular treatment is
increasing and has moved from PTA alone, to primary
placement of a stent.15–19 Currently there are no data
available from randomized trials, comparing surgical
and endovascular treatment. Due to low prevalence of
CSS it is questionable if there will ever be any. Our
technical and clinical experience with endovascular
treatment of patients with CSS was analyzed in order to
shed further light on this approach.
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Patients and Methods
The Medisch Spectrum Twente Hospital is a nation-
wide, tertiary referral centre for evaluation of patients
with suspicion of CSS in The Netherlands (16 million
inhabitants). Amulti-disciplinary study-group formed
by a vascular surgeon, gastro-enterologist and radiol-
ogist, participated in evaluation of all patients sus-
pected for CSS.
From July 1996 to December 2002, 278 consecutive
patients with the suspicion of CSS were evaluated.
This evaluation consisted of gastric exercise tonome-
try,20 splanchnic artery duplex ultra-sonography,
multi-plane abdominal aorta angiography both during
in- and exspiration and selective splanchnic artery
angiography. The diagnosis CSS was made in patients
with a medical history and presentation that fitted, in
combination with a significant stenotic lesion in one or
more splanchnic arteries confirmed functionally with
gastric exercise tonometry and anatomically by duplex
and angiography.
After discussion of all the results in the study-group
CSS was diagnosed in 97 patients (59 patients single
vessel, 33 patients 2-vessel, five patients 3-vessel CSS)
and rejected in 163 patients. The remaining group of 18
patients, with a classic medical history and abnormal
tonometry, but without anatomic proof for stenosis;
were treated conservatively. In the 97 patients with
CSS operative treatment was performed in 70, endo-
vascular treatment in 27 patients (Fig. 1). These 27
patients are the subject of this report. Patients with a
low risk for perioperative complications in combi-
nation with good long-term prognosis were selected
for open surgery. While higher risk patients with a
moderate to poor long-term prognosis were treated by
the endovascular technique. Primary stenting with a
balloon expandable stent is the preferred endovascu-
lar treatment. In short non-calcified, non-ostial lesions
PTA alone was used.
The endovascular procedure was performed in the
angio-suite, where the most optimal conditions for
positioning and imaging were available. The pro-
cedure consisted of simultaneous Seldinger catheter-
ization of the common femoral and brachial arteries. A
calibration catheter was positioned in the abdominal
aorta via the femoral artery, in order to simplify
identification of the origins of the coeliac and superior
mesenteric artery. After intra-venous administration of
5000 units of heparin, a balloon expandable Bridgew
stent (AVE-Medtronic) was placed via the brachial
artery (Fig. 2). One day before the procedure,
medication with salicylates was started (calcium
carbasalate 100 mg/day). Discharge, depending on
concomitant disease, was planned the day after the
procedure. Primary and secondary clinical success,
together with primary and secondary patency rates
were recorded for all patients (Fig. 3).
Results
The patients consisted of 14 men and 13 women with a
mean age of 62 years (median 65, range 28–81 years).
Nineteen out of 27 patients reported severe weight
loss. The body mass index (BMI) was 21 kg/m2 (range
17–28 kg/m2). Severe cardiac and/or pulmonary co-
morbidity or severe cachexia, were the main disqua-
lifying factors for operative revascularization, and was
present in 23 of 27 patients (85%). Out of 27 patients
with CSS, one patient had 3-vessel, 12 patients 2-vessel
and 14 patients 1-vessel stenosis (Table 1). All stenosis
were ostial lesions, or within the first 3 cm of the CA or
SMA. Five patients received splanchnic vascular
reconstructive treatment before (four in another
hospital, one was operated upon in the Medisch
Spectrum Twente hospital): two patients retrograde
venous bypasses to the SMA, in one patient in
combination with stenting of the CA. One patient
underwent an operative release of the CA and the last
two patients received a stent in the CA before.
An overview of the endovascular treatment of
different splanchnic arteries is shown in Table 2.
Three patients received angioplasty only; the other
24 patients underwent primary stent placement. Single
vessel revascularization was performed in 23 patients
(13 CA and 10 SMA); both CA and SMA revascular-
ization in the remaining four patients. Consequently
31 splanchnic arteries received angioplasty, including
stenting in 28 arteries. In hospital complications were
observed in three patients (11%): one patient devel-
oped a hematoma and neuropraxia of the arm
following brachial catheterization; in two other
patients the stent dislodged from the catheter during
angiography, necessitating operative removal from an
arm and a leg. Balloon inflation was experienced as
painful in some patients, especially during secondary
procedures. Hospital mortality was not observed.
The mean follow-up, including duplex ultrasound
was 19 months (median 14, range 2–76 months). Two
patients died, due to causes unrelated to CSS or the
endovascular treatment. One patient died from known
lung carcinoma, the other due to multiple organ failure
following gastric bleeding, 1 month after PTA of the
CA, resulting in gastric resection with death 6 months
after original endovascular treatment.
The primary clinical success, defined as full
recovery or significant improvement of symptoms
after the endovascular intervention, was 67% (18/27
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Fig. 1. Flowchart of 278 consecutive patients evaluated for the existence of Chronic splanchnic syndrome (CSS).
Table 1. Patient demographics and characteristics
Pt Sex M/F Age
(years)
Duration symptoms
(months)
Severe
co-morbidity
Vessels involved Previous
treatment
Atherosclerosis
(c ¼ central)
(p ¼ peripheral)
CA SMA IMA
1 F 69 24 þ þ þ 2 2
2 F 54 23 þ þ þ 2 c
3 M 75 7 þ þ 2 2
4 M 81 60 þ þ 2 c
5 M 51 15 þ þ þ 2 c
6 F 68 6 þ þ þ þ 2 p
7 M 81 5 þ þ 2 2
8 F 56 22 þ þ 2 2
9 M 69 6 þ þ þ 2 c þ p
10 M 61 15 þ þ þ 2 c
11 F 76 13 þ þ þ 2 c
12 M 55 16 þ þ þ 2 c þ p
13 M 72 .27 yrs þ þ 2 2
14 F 72 16 þ þ 2 p
15 F 65 7 þ þ þ 2 c
16 M 57 8 þ þ 2 c
17 F 35 5 2 þ 2 2
18 M 70 17 þ þ þ 2 c
19 F 56 15 2 þ 2 2
20 M 59 26 þ þ 2 2
21 M 57 .48 þ þ SMA bypass 2
22 F 67 7 þ þ þ 2 c þ p
23 M 69 12 þ þ 2 p
24 F 42 4 þ þ þ SMA bypass þ stent CA 2
25 M 68 23 þ þ PTA þ stent CA p
26 F 57 .60 2 þ þ PTA þ stent CA c
27 F 28 48 2 þ Release CA 2
Pt, patient; M, male; F, female; CA, celiac artery; SMA, superior mesenteric artery; IMA, inferior mesenteric artery; þ , means present; 2
means absent.
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Fig. 2. Stent placement endovascular stent placement in the celiac and the superior mesenteric artery in a patient with 2-vessel CSS. The procedure consisted of
simultaneous Seldinger catheterization of the common femoral and brachial artery. Following heparinization two balloon expandable Bridgew stents were placed in
the SMA and CA.
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patients). Re-intervention was performed in five
patients (19%), all anatomically successful, by the
endovascular (4) or open surgical (1) technique. Three
patients underwent a redo-PTA of a stent placed in the
CA, one patient redo-PTA and stent placement of
the SMA and CA, and one patient was revascularized
operatively after occlusion of a retrograde venous
SMA bypass and a CA stent. One of the patients
remained symptomatic following re-intervention.
Secondary clinical success summarized clinical
outcome after primary (18 patients) and re-interven-
tions (four successful patients out of five re-interven-
tions) and was 81% (22/27 patients). Five patients
claimed no improvement but duplex and tonometry
did not show any re- or residual stenosis.
The primary patency, functional revascularization
of an artery, without any re-interventions, was 81%.
Twenty-five out of a total number of 31 treated arteries
were primarily patent. Secondary patency, functional
revascularization of arteries, including the effective re-
interventions was 100% (31/31 arteries). Although five
patients remained symptomatic, their reconstructions
were patent.
Discussion
The present study showed that patients, unfit for
operative revascularization benefit from endovascular
treatment in more than 80% of cases, with an
acceptable complication rate and without procedure
or CSS related mortality. The anatomical results in
short term follow up were good, especially if second-
ary endovascular procedures were included. The less
satisfying clinical result in this series was a matter of
proper patient selection, because in all five patients
without improvement of symptoms, the anatomical
revascularization was successful and the gastric
exercise tonometry normalized. This indicates that
the pre-intervention symptoms were not caused by
insufficient splanchnic circulation. Series including
only patients with typical ‘angina intestinale’ reported
the best clinical results.4 With surgical revasculariza-
tion, excellent patency is achieved, but the overall
complication rate of 29%, and mortality up to 7% in
operative procedures gives rise to concern.18 In this
light endovascular treatment of CSS is a fair alterna-
tive to surgical revascularization in selected patients.
Moreover, endovascular treatment could delay the
necessity for surgical revascularization, until severe
cachectic patients were in a better condition for
undergoing a large operation.
Duplex of the splanchnic arteries visualizes anat-
omy and flow in the CA and SMA as well as the upper
abdominal aorta. Splanchnic artery duplex is techni-
cally possible in 85% of patients. Flow should be
measured during in- and exspiration. Different cutoff
points are used to identify stenosis during breathing.
However, the clinical impact of a stenosis seen with
duplex is unclear. MRA and CTA enable three-
dimensional visualization of splanchnic arteries and
veins. Digital subtraction angiography, however,
remains the gold standard imaging technique for
detection and classification of (severity of) stenotic
lesions in splanchnic arteries. Apart from a frontal
view of the abdominal aorta, it is crucial to obtain
lateral views of the splanchnic arteries, showing their
origins during in- and exspiration. This is the only way
to diagnose coeliac artery compression. Selective
Fig. 3. Gastric exercise tonometry.
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Table 2. Treatment, results and patency
Patient Previous
treatment
Treatment Primary clinical
success
Re-intervention Secondary clinical
success
Complications Follow-up
(months)
Comment
PTA Primary
stenting
CA SMA CA SMA
1 þ 2 2 Hematoma arm
Neuropraxia
6 No objective stenosis
2 þ þ þ 2 2 10
3 þ þ 2 Stent loss leg 27
4 þ þ 2 2 7
5 þ þ 2 2 26
6 þ þ 2 2 17
7 þ 2 2 2 50 No objective stenosis
8 þ þ 2 2 33
9 þ þ 2 2 23
10 þ þ þ 2 6 Died GI problem
11 þ þ 2 2 14
12 þ þ 2 2 5
13 þ þ 2 2 5
14 þ þ 2 2 7
15 þ þ 2 2 3
16 þ þ 2 2 36
17 þ þ 2 2 24
18 þ þ þ 2 2 2 Died lungca
19 þ 2 2 2 76 No objective stenosis
20 þ þ 2 2 55
21 SMA bypass þ (bypass) þ 2 2 8
22 þ þ 2 Re 2 PTA þ stent
CA þ SMA
þ 2 26
23 þ 2 Re-PTA þ re-stent
CA
þ 2 13 Wrong position
primary stent
24 SMA
bypass þ stent
CA
þ 2 Bypass CA þ 2 8
25 PTA þ stent CA þ 2 2 2 2 No objective stenosis
26 PTA þ stent CA þ 2 Re-PTA þ stent CA þ Stent loss arm 9 Primary stent
fracture
27 Release CA þ 2 Re-PTA CA 2 2 7 No objective stenosis
þ , means present; 2 , means absent; GI, gastro-intestinal.
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angiography shows collateral circulation and is essen-
tial in planning definitive treatment.
Tonometry measures the carbon dioxide level. With
gastric mucosal ischaemia CO2 will accumulate. The
tonometer, a nasogastric catheter with a balloon
connected at its tip, is positioned intra-gastric and
connected to a modified capnograph. With ischaemia,
the local pCO2 level will increase, compared to the
pCO2 in the circulation, causing a gradient. The level
of ischaemia is represented by the pCO2 gradient
(Fig. 2). Mucosal ischaemia is detected after a
moderate exercise test.20 In our experience gastric
exercise tonometry has proved itself a cornerstone
diagnostic tool as a functional test for mucosal
perfusion in CSS patients. Proper patient selection
using gastric exercise tonometry as functional test
enables the differentiation between CSD and CSS.
However, selection remains an issue since it is still not
clear if, and to what extent, abdominal symptoms
represent CSS, let alone if intervention is indicated.
Angioplasty of splanchnic arteries was first
reported by Furrer and coworkers in 1980.8 During
the past 23 years, only small series have reported on
angioplasty alone or in combination with various
types of stents.9–19 Most reports are unclear on patient
selection and number of stenotic lesions revascular-
ized. Analogous to renal artery disease, primary
stenting is the preferred endovascular treatment in
the case of calcified ostial lesions. A balloon expand-
able stent appears to be the best option because of the
high radial force resistance of such types of stents. Two
stents were lost during placement. This is inherent to
the type of balloon expandable stent that was used. A
new generation of balloon expandable stents, with
smaller diameters, more flexibility, better fixation to
the catheter and stronger radial force, has the promise
of further improvement of endovascular treatment of
CSS. The series does not report on endovascular
treatment of occluded splanchnic arteries. Recanalisa-
tion of longstanding occlusions is risky as perforation
and outflow dissection may result. Pinpoint stenosis
were successfully treated as long as the thinnest wire
available could get through the stenosis. Long stenosis
can be treated as long as relevant branching vessels do
not become overstented. The coeliac artery com-
pression syndrome is not eligible for endovascular
intervention, since the extraluminal tight compression
of the CA by the arcuate ligament is not durably
pushed aside with any type of stent. The use of a
transfemoral catheter is not obligatory, but the
calibrated catheter facilitates exact positioning of the
stent. Also, it is possible to obtain contrast imaging
after stent placement with the wire in situ. Some
complications of endovascular treatment are related to
the entry in the brachial artery, which may be reduced
by ultrasound guided arterial puncture. The solitary
femoral approach is now used more often; however
unlike the more horizontal renal ostia, the CA and
SMA sometimes angle sharply with the aorta, making
a distal approach impossible for precise positioning of
a rather stiff stent. There were no patients with acute or
sub-acute splanchnic ischaemia included in this series.
In general there is a strong feeling that in this group
of patients the splanchnic circulation should be
revascularized with primary stenting if possible, in
order to buy time for adequate diagnostic work up and
improvement of the physical and alimentary condition
of the patient involved. This should be considered
when operating on patients with acute on chronic
splanchnic ischaemia, because a significantly higher
mortality is observed in patients with a BMI of less
than 19.0 kg/m2. In case of ongoing peritonitis a
laparoscopy or laparotomy is advised to assess the
existence of transmural necrosis.
CSS is encountered infrequently. Well-known large
institutions report only limited numbers. Therefore,
few clinics will accumulate sufficient case material to
develop principles of treatment based on level 1
evidence. Moreover, literature describing CSS does
not include large-scale natural history studies, nor
randomized or controlled clinical trials.21
The present study suggests that the endovascular
treatment of CSS is low risk, technically challenging
and has reasonable long-term outcomes. We rec-
ommend endovascular treatment for CSS especially
for those patients with a high co-morbidity or a short
life expectancy.
Acknowledgements
R.H. Geelkerken and A.B. Huisman are proctors for Medtronic AVE.
References
1 Croft RJ,Menon GP, Marston A. Does intestinal angina exist?
A critical study of obstructed visceral arteries. Br J Surg 1981;
68(5):316–318.
2 Thomas JH, Blake K, Pierce GE, Hemreck AS, Seigel E. The
clinical course of asymptomaticmesenteric arterial stenosis. J Vasc
Surg 1998; 27(5):840–844.
3 Jimenez JG, Huber TS, Ozaki CK, Flynn TC, Berceli SA, Lee
WA, Seeger JM. Durability of antegrade synthetic aorto-
mesenteric bypass for chronic ischemia. J Vasc Surg 2002; 35(6):
1078–1084.
4 Geelkerken RH, van Bockel JH, de Roos WK, Hermans J,
Terpstra JL. Chronic mesenteric vascular syndrome: results of
reconstructive surgery. Arch Surg 1991; 126(9):1101–1106.
5 Calderon M, Reul GJ, Gregoric ID, Jacobs MJ, Duncan JM,
Ott DA, Livesay JJ, Cooley DA. Long-term results of the
Endovascular Treatment of Chronic Splanchnic Syndrome 199
Eur J Vasc Endovasc Surg Vol 28, August 2004
surgical management of symptomatic chronic intestinal ische-
mia. J Cardiovasc Surg (Torino) 1992; 33(6):723–728.
6 Park WM, Cherry Jr KJ, Chua HK, Clark RC, Jenkins G,
Harmsen WS, Noel AA, Panneton JM, Bower TC, Hallett Jr
JW, Gloviczki P. Current results of open revascularization for
chronic mesenteric ischemia: a standard for comparison. J Vasc
Surg 2002; 35(5):853–859.
7 Mateo RB, O’Hara PJ, Hertzer NR, Mascha EJ, Beven EG,
Krajewski LP. Elective surgical treatment of symptomatic
chronic mesenteric occlusive disease: early results and late
outcomes. J Vasc Surg 1999; 29(5):821–832.
8 Furrer J, Gruntzig A, Kugelmeier J, Goebel N. Treatment of
abdominal angina with percutaneous dilatation of an arteria
mesenterica superior stenosis. Cardiovasc Intervent Radiol 1980;
3(1):43–44.
9 Allen RC, Martin GH, Rees CR, Rivera FJ, Talkington CM,
Garret WV, Smith BL, Pearl GJ, Diamond NG, Lee SP,
Thompson JE. Mesenteric angioplasty in the treatment of chronic
intestinal ischemia. J Vasc Surg 1996; 24(3):415–423.
10 McShaneMD, Proctor A, Spencer P, Cumberland DC,Welsh
CL. Mesenteric angioplasty for chronic intestinal ischemia.
Cardiovasc Intervent Radiol 1998; 21(4):305–313.
11 Hallisey MJ, Deschaine J, Illescas FF, Sussman SK, Vine HS,
Okhi SK, Straub JJ. Angioplasty for the treatment of visceral
ischemia. Radiology 1988; 167(1):59–62.
12 Hackworth CA, Leef JA. Percutaneous transluminal mesenteric
angioplasty. J Vasc Surg 1998; 27(5):840–844.
13 Maspes F, di Pietralata GM, Gandini R, Innocenzi L,
Lupattelli L, Barzi F, Simonetti G. Percutaneous translumianl
angioplasty in the treatment of chronic mesenteric ischemia:
results and follow-up in 23 patients. Abdom Imaging 1998; 23:
358–363.
14 Rose SC, Quigley TM, Raker EJ. Revascularization for chronic
mesenteric ischemia: comparison of operative arterial bypass
grafting and percutaneous transluminal angioplasty. J Vasc Interv
Radiol 1999; 10(7):861–867.
15 Sheeran SR,Murphy TP, Khwaja A, Sussman SK,HalliseyMJ.
Stent placement for treatment of mesenteric artery stenoses or
occlusions. Eur J Vasc Surg 1992; 6(3):333–336.
16 Nyman U, Ivancev K, Lindh M, Uher P. Endovascular
treatment of chronic mesenteric ischemia: report of five cases.
J Vasc Interv Radiol 1995; 6(5):785–791.
17 Steinmetz E, Tatou E, Favier-Blavoux C, Bouchot O, Cognet
F, Cercueil JP, Krause D, David M, Brenot R. Endovascular
treatment as first choice in chronic intestinal ischemia. Ann Vasc
Surg 2002; 16(6):693–699.
18 Kasirajan K, O’Hara PJ, Gray BH, Hertzer NR, Clair DG,
Greenberg RK, Krajewski LP, Beven EG, Ouriel K. Chronic
mesenteric ischemia: open surgery versus percutaneous angio-
plasty and stenting. J Vasc Surg 2001; 33(1):63–71.
19 Matsumoto AH, Angle JF, Spinosa DJ, Hagspiel KD, Cage DL,
Leung DA, Kern JA, Tribble CG, Kron IL. Percutaneous
transluminal angioplasty and stenting in the treatment of chronic
mesenteric ischemia: results and long term follow up. J Am Coll
Surg 2002; 194: S22–31.
20 Otten JA, Oostveen E, Geelkerken RH, Groeneveld AB,
Kolkman JJ. Exercise induced ischemia in healthy volunteers a
tonometry study. J Appl Physiol 2001; 91:866–871.
21 Taylor LM, Moneta GL, Porter JM. In: Rutherford, ed.
Treatment of chronic visceral ischemia. Vascular Surgery, vol. 112.;
2000: 1533–1541.
Accepted 21 April 2004
J. L. van Wanroij et al.200
Eur J Vasc Endovasc Surg Vol 28, August 2004
